![Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204521006586-gr1.gif)
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect
![24-vuotias Poppy luuli kehonsa reagoivan huonosti raskauteen – oireiden karmiva syy paljastui kaksi päivää ennen vauvan syntymistä - MTVuutiset.fi 24-vuotias Poppy luuli kehonsa reagoivan huonosti raskauteen – oireiden karmiva syy paljastui kaksi päivää ennen vauvan syntymistä - MTVuutiset.fi](https://im.mtvuutiset.fi/image/7849414/landscape16_9/1600/900/d251789a4b4e1b1a5ef0ce28935ebc29/Zb/shutterstock-52133623-1.jpg)
24-vuotias Poppy luuli kehonsa reagoivan huonosti raskauteen – oireiden karmiva syy paljastui kaksi päivää ennen vauvan syntymistä - MTVuutiset.fi
![Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204522X00028-cov150h.gif)
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect
![Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram](https://i1.rgstatic.net/publication/324361774_A_pilot_study_of_durvalumab_and_tremelimumab_and_immunogenomic_dynamics_in_metastatic_breast_cancer/links/5acba201a6fdcc8bfc85fb30/largepreview.png)
Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram
![Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram](https://www.researchgate.net/publication/324361774/figure/fig5/AS:613556806488070@1523294750799/Exploratory-characterization-of-B-cells-in-patient-with-pseudoprogression-A_Q320.jpg)
Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram
![Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - ScienceDirect Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204520305416-gr1.gif)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - ScienceDirect
![Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204521006586-gr2.jpg)
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect
![Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204521006586-gr3.jpg)
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - ScienceDirect
![Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram Response to durvalumab and tremelimumab shown by (A) waterfall plot,... | Download Scientific Diagram](https://www.researchgate.net/publication/324361774/figure/fig1/AS:613556802318338@1523294749987/CONSORT-diagram_Q320.jpg)